PT  - JOURNAL ARTICLE
AU  - Kala M. Mehta
AU  - Maggie Yin
AU  - Cynthia Resendez
AU  - Kristine Yaffe
TI  - Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease
AID  - 10.1212/01.wnl.0000167545.38161.48
DP  - 2005 Jul 12
TA  - Neurology
PG  - 159--162
VI  - 65
IP  - 1
4099  - http://n.neurology.org/content/65/1/159.short
4100  - http://n.neurology.org/content/65/1/159.full
SO  - Neurology2005 Jul 12; 65
AB  - Acetylcholinesterase inhibitors (AChIs) have been demonstrated to improve Alzheimer disease symptoms. Whether the use of AChIs varies by ethnicity is unknown. More than 2500 ethnically diverse patients (6% African American, 14% Latino, and 7% Asian patients) from the Alzheimer’s Disease Research Centers in California were studied. Compared with white patients with AD, minority patients had 40% lower odds of AChI use (odds ratio 0.6, 95% confidence interval: 0.5 to 0.7).